Contraceptive Technology Update – November 1, 2015
November 1, 2015
View Issues
-
FDA approves first treatment for sexual desire disorder
The FDA has approved Addyi (flibanserin, Sprout Pharmaceuticals, Raleigh, NC) to treat acquired, generalized hypoactive sexual desire disorder in premenopausal women. The drug is the first such treatment to be approved by the FDA for this condition.
-
Oral contraceptives reduce the risk of developing endometrial cancer
Taking oral contraceptives, even for just a few years, offers significant long-term protection against endometrial cancer, confirms a detailed re-analysis of all available evidence by British researchers. Data indicate that the longer a woman takes oral contraceptives, the greater her reduction in risk for the disease, the analysis states.
-
Results of survey indicate unmet need for family planning at community health centers
Results of a recent survey at U.S. community health centers indicate an unmet need for more comprehensive family planning services at such facilities, according to a report issued by the Geiger Gibson /RCHN Community Health Foundation Research Collaborative and the Jacobs Institute of Women’s Health, all in Washington, DC.
-
Talk with women about pelvic pain — A high number might be going untreated
Results from a study by researchers at the National Institutes of Health and the University of Utah School of Medicine, Salt Lake City suggest a high proportion of reproductive-age women might be experiencing pelvic pain that goes untreated.
-
Planned Parenthood controversy spurs attacks on family planning funding
The often-quiet summer months in Washington, DC, were roiled this year by videos attacking Planned Parenthood Federation of America and its affiliates for facilitating the donation of fetal tissue at the request of some women having an abortion. The organization has strongly denied any wrongdoing, and multiple state investigations have turned up no evidence that it has profited off of such donations or otherwise violated the law.
-
Research eyes use of tenofovir to impact herpes
The race is on to prevent the spread of herpes simplex virus type 2 infection, the most common cause of genital ulcer disease. In 2012, about 417 million sexually active adults ages 15-49 years had an existing prevalent HSV-2 infection.